{
    "clinical_study": {
        "@rank": "107721", 
        "arm_group": [
            {
                "arm_group_label": "AML-Intensive Chemotherapy", 
                "arm_group_type": "Other", 
                "description": "Patients with Acute Myeloid Leukemia fit for intensive chemotherapy Patients will receive Induction Chemotherapy, and CR will be evaluated after 28 days.\nPatients who achieve CR post-induction chemotherapy will receive post-remission therapy according to risk:\nLow risk patients: Consolidation chemotherapy or Autologous stem cell transplantation\nIntermediate and high-risk patients: Allogeneic stem cell transplantation Patients who do not achieve CR may receive one second induction cycle, and if CR is achieved may proceed to post-remission therapy as per above. Patients who do not achieve CR after two cycles of induction will be deemed refractory and removed from the study."
            }, 
            {
                "arm_group_label": "AML-Non-intensive chemotherapy", 
                "arm_group_type": "Other", 
                "description": "Patients with acute myeloid leukemia not fit for intensive chemotherapy Patients will receive induction chemotherapy with either low dose cytarabine or decitabine. Assignment to each drug will depend on drug availability and physician discretion. No randomization will be done between the drugs.\nCycles will be repeated every 28 days. Patients who achieve CR will continue to post-consolidation therapy with either cytarabine or decitabine, based on the induction therapy received. Patients will receive a maximum of 4 cycles until achieving CR, if no response is seen after 4 cycles patients will be deemed refractory."
            }, 
            {
                "arm_group_label": "Chronic Myeloid Disorders", 
                "arm_group_type": "No Intervention", 
                "description": "Patients with Chronic Myeloid Disorders:\nMyeloproliferative Neoplasms\nMyelodysplastic Syndromes\nMyeloproliferative/Myelodysplastic Neoplasms"
            }
        ], 
        "brief_summary": {
            "textblock": "The objective of this study is to describe the prevalence and prognostic impact of the most\n      common genetic abnormalities in patients with Myeloid Neoplasms, including Acute Myeloid\n      Leukemia (AML), Myeloproliferative Neoplasms (MPN), Myelodysplastic Syndromes (MDS) and\n      Myeloproliferative/Myelodysplastic Neoplasms. Patients will have samples of blood and/or\n      bone marrow collected and sent to Hospital Israelita Albert Einstein for analysis and\n      storage.\n\n      Patients with a diagnosis of Acute Myeloid Leukemia will be treated according to an uniform\n      protocol."
        }, 
        "brief_title": "Study of Molecular and Genetic Abnormalities in Patients With Myeloid Neoplasms", 
        "completion_date": {
            "#text": "December 2019", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Acute Myeloid Leukemia", 
            "Myeloproliferative Neoplasms", 
            "Myelodysplastic Syndromes", 
            "Myeloproliferative/Myelodysplastic Neoplasm"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Congenital Abnormalities", 
                "Neoplasms", 
                "Leukemia", 
                "Leukemia, Myeloid, Acute", 
                "Leukemia, Myeloid", 
                "Myelodysplastic Syndromes", 
                "Preleukemia", 
                "Myeloproliferative Disorders"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Acute Myeloid Leukemia-Intensive Chemotherapy\n\n        Inclusion Criteria:\n\n          -  Diagnosis of AML according to WHO criteria\n\n          -  Age greater than 18 years\n\n          -  Performance status (ECOG) between 0-2\n\n          -  Adequate liver and kidney function\n\n          -  Signed Informed Consent form\n\n          -  No prior therapy for AML, except use of hydroxyurea for control of elevated white\n             blood cell counts\n\n          -  Adequate contraception for fertile men and women\n\n          -  Eligible for intensive chemotherapy (as judged by the treating physician)\n\n        Exclusion Criteria:\n\n          -  Acute myeloid leukemia with retinoic acid receptor alpha (RARA) translocations (APL,\n             acute promyelocytic leukemia)\n\n          -  Pregnant women\n\n          -  HIV-positivity\n\n          -  New York Heart Association class III and IV congestive heart failure\n\n          -  Patient refuses to use adequate contraception\n\n          -  History of hypersensibility to any of the used chemotherapy drugs\n\n          -  Patient refuses to sign informed consent form\n\n        Acute Myeloid Leukemia-Non-Intensive Chemotherapy\n\n        Inclusion Criteria:\n\n          -  Diagnosis of AML according to WHO criteria\n\n          -  Age greater than 18 years\n\n          -  Signed Informed Consent form\n\n          -  No prior therapy for AML, except use of hydroxyurea for control of elevated white\n             blood cell counts\n\n          -  Adequate contraception for fertile men and women\n\n          -  Non-eligible for intensive chemotherapy (as judged by the treating physician)\n\n        Exclusion Criteria:\n\n          -  Acute myeloid leukemia with RARA translocations (APL, acute promyelocytic leukemia)\n\n          -  Pregnant women\n\n          -  HIV-positivity\n\n          -  Patient refuses to use adequate contraception\n\n          -  History of hypersensibility to any of the used chemotherapy drugs\n\n          -  Patient refuses to sign informed consent form\n\n        Chronic Myeloid Disorders:\n\n        Inclusion Criteria:\n\n          -  Diagnosis of Myeloproliferative Neoplasm or Myelodysplastic Syndrome or\n             Myeloproliferative/Myelodysplastic Neoplasm according to WHO criteria\n\n          -  Age greater than 18 years\n\n          -  Signed Informed Consent form\n\n        Exclusion Criteria:\n\n          -  Patient refuses to sign informed consent form"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "450", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "January 2, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02084563", 
            "org_study_id": "LMA Brasil", 
            "secondary_id": "11/1714"
        }, 
        "intervention": [
            {
                "arm_group_label": "AML-Intensive Chemotherapy", 
                "description": "Induction chemotherapy for patients with AML eligible for intensive chemotherapy:\nCytarabine 200 mg/m2 IV continuous infusion days 1-7\nDaunorubicin 90 mg/m2 intravenous piggyback  days 1-3", 
                "intervention_name": "Induction Chemotherapy", 
                "intervention_type": "Drug", 
                "other_name": [
                    "7+3", 
                    "Ara-C", 
                    "Daunorubicin", 
                    "Anthracycline", 
                    "3+7"
                ]
            }, 
            {
                "arm_group_label": "AML-Intensive Chemotherapy", 
                "description": "Consolidation chemotherapy for patients eligible for intensive chemotherapy with low-risk AML or patients with intermediate-/high-risk AML who do not have matched donors:\n-Cytarabine 1.5 g/m2 IV in 3 hours days 1, 3 and 5 for 3 cycles", 
                "intervention_name": "Consolidation Chemotherapy", 
                "intervention_type": "Drug", 
                "other_name": [
                    "Ara-C", 
                    "Cytarabine"
                ]
            }, 
            {
                "arm_group_label": "AML-Intensive Chemotherapy", 
                "description": "Autologous Stem Cell Transplantation for consolidation of patients eligible for intensive chemotherapy with low-risk AML or patients with intermediate-/high-risk AML who do not have matched donors:\nBusulfan 1 mg/Kg PO q6h or 130 mg/m2 IV once daily days -7 to -4\nCyclophosphamide 60 mg/Kg IV once daily days -3 and -2", 
                "intervention_name": "Autologous Stem Cell Transplantation", 
                "intervention_type": "Drug", 
                "other_name": [
                    "ASCT", 
                    "Autologous Bone Marrow Transplantation", 
                    "ABMT"
                ]
            }, 
            {
                "arm_group_label": "AML-Intensive Chemotherapy", 
                "description": "Allogeneic Stem Cell Transplantation for consolidation of patients eligible for intensive chemotherapy with intermediate-/high-risk AML\nConditioning regimen:\nBusulfan 1 mg/Kg PO q6h or 130 mg/m2 IV once daily days -7 to -4\nCyclophosphamide 60 mg/Kg IV once daily days -3 and -2 or Fludarabine 40 mg/m2 IV once daily days -7 to -4", 
                "intervention_name": "Allogeneic Stem Cell Transplantation", 
                "intervention_type": "Drug", 
                "other_name": [
                    "AlloSCT", 
                    "Allogeneic Bone Marrow Transplantation"
                ]
            }, 
            {
                "arm_group_label": "AML-Non-intensive chemotherapy", 
                "description": "Chemotherapy for patients with AML who are not fit for intensive chemotherapy:\nCytarabine 60 mg/m2 subcutaneous (SQ) bid days 1-5 (until CR or maximum 4 cycles)\nCytarabine 40 mg/m2 SQ bid days 1-5 (after CR, until a maximum of 3 years of therapy or relapse, whichever comes first)", 
                "intervention_name": "Low Dose Cytarabine", 
                "intervention_type": "Drug", 
                "other_name": [
                    "Low dose cytarabine", 
                    "Low dose ara-C", 
                    "LDAC"
                ]
            }, 
            {
                "arm_group_label": "AML-Non-intensive chemotherapy", 
                "description": "Chemotherapy for patients with AML who are not fit for intensive chemotherapy:\nDecitabine 20 mg/m2 IV once daily days 1-10 (until CR or maximum 4 cycles)\nDecitabine 20 mg/m2 IV once daily days 1-5 (after CR, until a maximum of 3 years of therapy or relapse, whichever comes first)", 
                "intervention_name": "Decitabine", 
                "intervention_type": "Drug", 
                "other_name": [
                    "2-aza-5\u00b4-deoxycytidine", 
                    "Dacogen", 
                    "DAC"
                ]
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Cytarabine", 
                "Decitabine", 
                "Daunorubicin"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Acute Myeloid Leukemia", 
            "Myeloproliferative Neoplasms", 
            "Myelodysplastic Syndromes", 
            "Myeloproliferative/Myelodysplastic Neoplasm", 
            "Leukemia", 
            "MDS", 
            "MPN", 
            "AML", 
            "Chronic myelomonocytic leukemia (CMML)", 
            "Polycythemia Vera (PV)", 
            "Essential Thrombocythemia (ET)", 
            "Myelofibrosis (MF)"
        ], 
        "lastchanged_date": "March 10, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Sao Paulo", 
                    "country": "Brazil", 
                    "state": "SP", 
                    "zip": "05651901"
                }, 
                "name": "Hospital Israelita Albert Einstein"
            }, 
            "investigator": [
                {
                    "last_name": "Fabio P Santos, MD", 
                    "role": "Principal Investigator"
                }, 
                {
                    "last_name": "Ricardo Helman, MD", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Paulo V Campregher, MD", 
                    "role": "Sub-Investigator"
                }
            ], 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Brazil"
        }, 
        "number_of_arms": "3", 
        "official_title": "Evaluation of the Incidence and Prognostic Impact of Molecular and Genetic Abnormalities in Patients With Acute Myeloid Leukemia, Myelodysplastic Syndrome and Myeloproliferative Neoplasms", 
        "overall_contact": {
            "email": "isabel.bello@einstein.br", 
            "last_name": "Isabel Bello, RN", 
            "phone": "+55-11-2151-1128"
        }, 
        "overall_contact_backup": {
            "email": "sandra.nakashima@einstein.br", 
            "last_name": "Sandra Nakashima, RN", 
            "phone": "+55-11-2151-1128"
        }, 
        "overall_official": [
            {
                "affiliation": "Hospital Israelita Albert Einstein", 
                "last_name": "Fabio P Santos, MD", 
                "role": "Study Director"
            }, 
            {
                "affiliation": "Hospital Israelita Albert Einstein", 
                "last_name": "Nelson Hamerschlak, MD, PhD", 
                "role": "Study Chair"
            }
        ], 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Brazil: Ethics Committee", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "As assessed by results of molecular and cytogenetic tests and frequency in the population studied", 
            "measure": "Prevalence of molecular and cytogenetic abnormalities", 
            "safety_issue": "No", 
            "time_frame": "2 years"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02084563"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Hospital Israelita Albert Einstein", 
            "investigator_full_name": "Fabio Pires de Souza Santos", 
            "investigator_title": "MD", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "description": "Evaluation of 5-years overall survival in patients with Acute Myeloid Leukemia, Myeloproliferative Neoplasms, Myelodysplastic Syndromes and Myeloproliferative/Myelodysplastic Neoplasms", 
                "measure": "Overall survival", 
                "safety_issue": "No", 
                "time_frame": "5 years"
            }, 
            {
                "description": "Evaluate complete remission (CR) rate at 1 month for patients with Acute Myeloid Leukemia who received induction chemotherapy. Complete remission was defined by the presence of < 5% blasts in the bone marrow (BM) with > 1 x 10^9/L neutrophils and >100x10^9/L platelets in the peripheral blood (PB)", 
                "measure": "Response rate", 
                "safety_issue": "No", 
                "time_frame": "1 month"
            }, 
            {
                "description": "Evaluate rate of 5-years disease-free survival in patients with Acute Myeloid Leukemia who enter complete remission after induction chemotherapy", 
                "measure": "Disease Free Survival", 
                "safety_issue": "No", 
                "time_frame": "5 years"
            }, 
            {
                "description": "Evaluate 5-years cumulative incidence of relapse and non-relapse mortality in patients with Acute Myeloid Leukemia who achieve complete remission following induction chemotherapy", 
                "measure": "Cumulative incidence of relapse and non-relapse mortality", 
                "safety_issue": "No", 
                "time_frame": "5 years"
            }, 
            {
                "description": "Evaluate hematological and non-hematological toxicity in patients with Acute Myeloid Leukemia treated according to the protocol. Toxicity will be graded as per the National Cancer Institute Common Toxicity Criteria for Adverse Events v4.0.3", 
                "measure": "Number of participants with adverse events as a measure of safety and tolerability", 
                "safety_issue": "Yes", 
                "time_frame": "1 year"
            }, 
            {
                "description": "Evaluate 5-years incidence of transformation to Acute Myeloid Leukemia in patients with Myeloproliferative Neoplasms, Myelodysplastic Syndromes and Myeloproliferative/Myelodysplastic Neoplasms", 
                "measure": "Cumulative Incidence of Transformation to Acute Myeloid Leukemia", 
                "safety_issue": "No", 
                "time_frame": "5 years"
            }
        ], 
        "source": "Hospital Israelita Albert Einstein", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Hospital Israelita Albert Einstein", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "October 2012", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}